

# FRANCE

## Recent and planned developments in pharmaceutical policies 2014

### Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<p><b>Pricing:</b></p> <p>Price reduction' policy continues and enables the social security to save about 800M€ both in 2013 and 2014.</p> <p>Among the main changes :</p> <p>(1) New "TFR" created, others have been lowered</p> <p>(2) Official prices for several costly products (orphan, anti-cancer)</p> <p><b>VAT:</b></p> <p>No changes since May</p> <p><b>Margins:</b></p> <p>(3) The fix part of pharmacists remuneration should increase in two steps by 2016. New margin parameters have been negotiated with pharmacists and should be enforced on the 1st of January 2015 and then on the 1st of January 2016.</p> <p>The agreement with pharmacists was signed on 05/21/2014.</p> <p>The official approbation by the government should be published soon.</p>	<p>Rosuvastatin and Ezetimibe prescriptions for new patients now need prior approval by the Health Insurance in order to be reimbursed</p>
S P E C I A L  T O P I C	Other changes related to medicines	
	<p>If the expenditures for the treatment of hepatitis C exceed a certain amount (fixed by law) and have increased by more than 10% since the previous year, manufacturers of the drugs related to these expenditures might be subject to a tax (still under discussion, might be voted mid/end December).</p> <p>Single unit dispensation of antibiotics is under experiment in 4 regions.</p>	
Policies related to high cost medicines		